N-Zyme Biomedical Raises Series A Funding
N-Zyme Biomedical, a company based in Milwaukee, Wisconsin, has raised $4.6 million in a Series A funding round. The company focuses on developing a treatment for Laryngopharyngeal Reflux, aiming to provide a solution that is safe, effective, and efficient.
Company Leadership
The company is led by Co-Founder and CEO Franco Vigile. Under his leadership, N-Zyme Biomedical has been working towards innovative treatments for conditions related to Laryngopharyngeal Reflux, a digestive disorder that affects the throat and voice box.
Investors
Details regarding the specific investors for this funding round have not been disclosed. The absence of a lead investor was noted, and no other investors were named in the announcement.
Planned Use of Funds
While specific plans for the newly acquired capital were not detailed, companies in similar stages often allocate funds towards research and development, expanding product offerings, and potentially increasing market reach. It is likely that N-Zyme Biomedical will use the funds to further develop its treatment solutions and support any necessary clinical trials.
Conclusion
This funding marks a significant step for N-Zyme Biomedical as it continues to develop its treatment for Laryngopharyngeal Reflux. The new capital will likely support the company's efforts to advance its research and bring its solutions closer to market.